中华急诊医学杂志
中華急診醫學雜誌
중화급진의학잡지
CHINESE JOURNAL OF EMERGENCY MEDICINE
2012年
7期
746-750
,共5页
苏伟%杨智%许东琳%杨自力
囌偉%楊智%許東琳%楊自力
소위%양지%허동림%양자력
血液灌流%脓毒症休克%炎症介质%APCHEⅡ评分%内毒素
血液灌流%膿毒癥休剋%炎癥介質%APCHEⅡ評分%內毒素
혈액관류%농독증휴극%염증개질%APCHEⅡ평분%내독소
Hemoperfusion%Septic shock%Inflammation mediator%APCHE Ⅱ score%Endotoxin
目的 评价采用中性树脂的直接血液灌流(NS-DHP)治疗革兰氏阴性杆菌脓毒血症的临床疗效及安全性.方法 广州市第一人民医院重症医学科2008年至2010年革兰氏阴性杆菌脓毒血症42例,随机(随机数字法)分为治疗组(D组)18例和对照组(C组)24例.两组患者均予脓毒症集束化治疗,D组在确诊后即行NS-DHP治疗.采用Baxter床旁连续性血液净化机,使用HA330血液灌流器治疗,使用低分子肝素抗凝,血液灌流每次治疗2.5h,每隔24h治疗1次,连续治疗3次.两组患者分别于治疗前及治疗24、48、72 h时点监测APACHEⅡ评分、氧合指数(0I)、平均动脉压(MAP)、多巴胺用量(DA),静脉采血监测血浆内毒素水平(ET)、血清TNF-α水平、IL-6水平、IL-10水平和C反应蛋白水平(CRP),并比较两组患者28d病死率及ICU 停留时间.结果 D组患者均能耐受血液灌流治疗,无不良并发症发生.两组患者均未接受连续性肾替代治疗.与治疗前比较,两组在治疗24、48、72h时点,其APACHEⅡ评分、DA、CRP、ET、TNF-α及IL-6水平均有显著下降(P<0.05),OI、MAP均明显上升(P<0.05),而IL-10比较差异均无统计学意义.在治疗24、48、72h时点,D组的APACHEⅡ评分、DA、CRP、TNF-α及IL-6水平均低于C组( P<0.05),而Ol和MAP均高于C组(P<0.05),但两组间ET、IL-10比较差异均无统计学意义.结论 早期采用中性树脂的血液灌流可降低革兰氏阴性菌脓毒症休克患者APACHEⅡ评分和多巴胺用量,降低C反应蛋白、TNF-α和IL-6水平,提高氧合指数及平均动脉压,而对内毒素水平、28 d病死率、ICU停留时间无影响.
目的 評價採用中性樹脂的直接血液灌流(NS-DHP)治療革蘭氏陰性桿菌膿毒血癥的臨床療效及安全性.方法 廣州市第一人民醫院重癥醫學科2008年至2010年革蘭氏陰性桿菌膿毒血癥42例,隨機(隨機數字法)分為治療組(D組)18例和對照組(C組)24例.兩組患者均予膿毒癥集束化治療,D組在確診後即行NS-DHP治療.採用Baxter床徬連續性血液淨化機,使用HA330血液灌流器治療,使用低分子肝素抗凝,血液灌流每次治療2.5h,每隔24h治療1次,連續治療3次.兩組患者分彆于治療前及治療24、48、72 h時點鑑測APACHEⅡ評分、氧閤指數(0I)、平均動脈壓(MAP)、多巴胺用量(DA),靜脈採血鑑測血漿內毒素水平(ET)、血清TNF-α水平、IL-6水平、IL-10水平和C反應蛋白水平(CRP),併比較兩組患者28d病死率及ICU 停留時間.結果 D組患者均能耐受血液灌流治療,無不良併髮癥髮生.兩組患者均未接受連續性腎替代治療.與治療前比較,兩組在治療24、48、72h時點,其APACHEⅡ評分、DA、CRP、ET、TNF-α及IL-6水平均有顯著下降(P<0.05),OI、MAP均明顯上升(P<0.05),而IL-10比較差異均無統計學意義.在治療24、48、72h時點,D組的APACHEⅡ評分、DA、CRP、TNF-α及IL-6水平均低于C組( P<0.05),而Ol和MAP均高于C組(P<0.05),但兩組間ET、IL-10比較差異均無統計學意義.結論 早期採用中性樹脂的血液灌流可降低革蘭氏陰性菌膿毒癥休剋患者APACHEⅡ評分和多巴胺用量,降低C反應蛋白、TNF-α和IL-6水平,提高氧閤指數及平均動脈壓,而對內毒素水平、28 d病死率、ICU停留時間無影響.
목적 평개채용중성수지적직접혈액관류(NS-DHP)치료혁란씨음성간균농독혈증적림상료효급안전성.방법 엄주시제일인민의원중증의학과2008년지2010년혁란씨음성간균농독혈증42례,수궤(수궤수자법)분위치료조(D조)18례화대조조(C조)24례.량조환자균여농독증집속화치료,D조재학진후즉행NS-DHP치료.채용Baxter상방련속성혈액정화궤,사용HA330혈액관류기치료,사용저분자간소항응,혈액관류매차치료2.5h,매격24h치료1차,련속치료3차.량조환자분별우치료전급치료24、48、72 h시점감측APACHEⅡ평분、양합지수(0I)、평균동맥압(MAP)、다파알용량(DA),정맥채혈감측혈장내독소수평(ET)、혈청TNF-α수평、IL-6수평、IL-10수평화C반응단백수평(CRP),병비교량조환자28d병사솔급ICU 정류시간.결과 D조환자균능내수혈액관류치료,무불량병발증발생.량조환자균미접수련속성신체대치료.여치료전비교,량조재치료24、48、72h시점,기APACHEⅡ평분、DA、CRP、ET、TNF-α급IL-6수평균유현저하강(P<0.05),OI、MAP균명현상승(P<0.05),이IL-10비교차이균무통계학의의.재치료24、48、72h시점,D조적APACHEⅡ평분、DA、CRP、TNF-α급IL-6수평균저우C조( P<0.05),이Ol화MAP균고우C조(P<0.05),단량조간ET、IL-10비교차이균무통계학의의.결론 조기채용중성수지적혈액관류가강저혁란씨음성균농독증휴극환자APACHEⅡ평분화다파알용량,강저C반응단백、TNF-α화IL-6수평,제고양합지수급평균동맥압,이대내독소수평、28 d병사솔、ICU정류시간무영향.
Objective To evaluate clinical effect and safety of direct hemoperfusion with neutral resin (NS-DHP) on patients with septic shock caused by Gram-negative bacteria infection.Methods A total of 42 patients were enrolled in the study and randomly ( random number) divided into two groups.Patients of control group ( n =24) received sepsis bundle therapy,and patients of group D ( n =18 ) were treated with NS-DHP in addition to sepsis bundle therapy.HA330 hemoperfusion device were used in each patient of group D.The procedure of hemoparfusion lasted 2.5 hours and carried out trice a 24 hours.Clinical data including APCHE Ⅱ score,PO2/FiO2 (OI),mean arterial pressure (MAP),dopamine usage (DA),plasma level of endotoxin (ET),C-reactive protein (CRP),TNF-α,IL-6 and IL-10 were recorded during the treatment.Results Patients well tolerated NS-DHP without any complication in group D.All patients in both two groups did not receive long-term renal replacement therapy.At 24 h,48 h and 72 h after the initiation of treatment,APACHE Ⅱ score,O1,MAP,DA,ET,CRP,TNF-α and IL-6 improved obviously both groups (P <0.05),but there was no significant ditterence in serum levels of IL-10 in both groups.In the group D,APCHE Ⅱ score,OI,MAP,DA,CRP,TNF-α and IL-6 were improved more obviously than those in the group C (P <0.05) ).There was no significant difference in plasma levels of ET in both groups during the treatment.Conclusions NS-DHP can improve APACHE Ⅱ score,PO2/FiO2 and MAP in patients with septic shock caused by gram-negative bacteria infection and reduce the levels of CRP,TNF-α and IL-6,but has no effect on the levels of ET and IL-10 as well as on 28-day mortality and ICU stay.